EMBELINE E Drug Patent Profile
✉ Email this page to a colleague
When do Embeline E patents expire, and what generic alternatives are available?
Embeline E is a drug marketed by Hikma and is included in one NDA.
The generic ingredient in EMBELINE E is clobetasol propionate. There are fourteen drug master file entries for this compound. Thirty-nine suppliers are listed for this compound. Additional details are available on the clobetasol propionate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Embeline E
A generic version of EMBELINE E was approved as clobetasol propionate by COSETTE on February 16th, 1994.
Summary for EMBELINE E
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 80 |
Patent Applications: | 4,476 |
Formulation / Manufacturing: | see details |
DailyMed Link: | EMBELINE E at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for EMBELINE E
US Patents and Regulatory Information for EMBELINE E
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hikma | EMBELINE E | clobetasol propionate | CREAM;TOPICAL | 075325-001 | Dec 24, 1998 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |